Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

WHITEHOUSE STATION, N.J. – Merck & Co.’s is reporting a 14 per cent decline in fourth-quarter as generic competition cut into the sale of one-time blockbuster medicines, as well as unfavourable currency exchange rates that reduced overseas revenue.
The world’s third-biggest drugmaker reported net income of $781 million, or 26 cents per share on Wednesday, down from $908 million, or 30 cents per share, a year earlier.
The maker of Type 2 diabetes pill Januvia says that excluding one-time items, net income was $2.6 billion, or 88 cents per share. That’s a penny shy of Wall Street expectations, according to a poll by FactSet.
Revenue totalled $11.32 billion, down 4 per cent. Analysts expected $11.36 billion.
Merck, based in Whitehouse Station, N.J., forecast 2014 profit of $2.25 to $2.47 per share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.